NSE: SUVEN | BSE: 530239 | ASM

Download real time

184.97 0.86 (0.47%)

High volume today

NSE 15 May, 2025 3:31 PM (IST)

4,033.7

Market Cap

Above industry Median

1.1

Beta 1Year

High Volatility

Cohance Lifesciences Ltd. share price target and research reports

Name: Latest research reports of Cohance Lifesciences Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Cohance Lifesciences Ltd.
Rating: 5
Author: Geojit BNP Paribas

Latest analyst research reports with target prices and PDF download for SUVEN, BSE:530239 Cohance Lifesciences Ltd.

Search Inside the pdf :

Cohance Lifesciences Ltd.

21 Jan 2020

184.97

0.47%

Suven Life Sciences

Cohance Lifesciences Ltd.

ICICI Securities Limited

The equity shareholders of the company whose names are recorded in the register of members and records of the depositories as a member of the company as on January 22, 2020 will be entitled to allotment of one fully paid up equity share of face value of | 1 each of SPL (resulting company) that will be issued and allotted for every fully paid up equity share of face...

Cohance Lifesciences Ltd. has gained 84.51% in the last 1 Year

Cohance Lifesciences Ltd.

21 Nov 2019

184.97

0.47%

SUVEN LIFE SCIENCES LTD

Buy: Cohance Lifesciences Ltd.

Target

Geojit BNP Paribas

Q2FY20 revenue grew by ~200% YoY on account of higher sales in CRAMS (+186%) and specialty chemicals (currently 2 products) EBITDA & PAT registered a +300% growth each YoY on account of increase in high margin commercial CRAMS sales, lower employee cost & other expenses as a percentage of sales. Clinical trial data on molecule SUVN-502 which got delayed is expected to be available in 3 weeks time and will be presented in CTAD 2019 - Alzheimer Congress at San Diego, USA ....

Cohance Lifesciences Ltd. has gained 51.24% in the last 1 Month

Cohance Lifesciences Ltd.

26 Aug 2019

184.97

0.47%

SUVEN LIFE SCIENCES LTD

Buy: Cohance Lifesciences Ltd.

Recommendation Target

Geojit BNP Paribas

Q1FY20 revenue grew by a muted 4% YoY as uptick in specialty chemicals (+55%) was offset by degrowth in CRAMS (~17%YoY) and technical services (~40%YoY). EBITDA & PAT registered a 54%/47% growth YoY on account of...

Cohance Lifesciences Ltd. has gained 54.36% in the last 6 Months

Cohance Lifesciences Ltd.

29 May 2019

184.97

0.47%

SUVEN LIFE SCIENCES LTD

Hold: Cohance Lifesciences Ltd.

Recommendation Target

Geojit BNP Paribas

Q4FY19 revenue grew by 18% YoY driven by higher sales in CRAMS(~25%YoY) segment and Specialty chemicals (~16%YoY). EBITDA &PAT; registered a 15%/9% growth YoY while margin declined by 200bps in Q4FY19 and by 348bps in FY19. Molecule SUVN-502 will be presented at Alzheimer's Association International Conference at Los Angeles on 17th July 2019, which can fetch more than Rs +400cr if successful. We expect EBITDA margin to remain around 33% range for FY1921E considering lower growth momentum and maintain our...

Cohance Lifesciences Ltd. has gained 84.51% in the last 1 Year

Cohance Lifesciences Ltd.

28 May 2019

184.97

0.47%

Suven Life Sci

Buy: Cohance Lifesciences Ltd.

Dolat Capital

Nail biting wait with SUVN 502 data announcement Suven reported a strong performance during Q4FY19. Revenue grew 19% YoY, due to a 64% YoY rise in specialty chemicals. Core CRAMS grew 4% to ` 718mn, whereas commercial CRAMS fell 23% YoY to ` 420mn (` 800mn for FY19). CTS grew 26% YoY, including Taro royalty worth ` 24mn. The management expects commercial revenue to be in the range of ` 1.3mn in FY20 and flat specialty chemicals. SUVN 502 could be a positive trigger, if the data is favourable. Based on a conservative approach, we estimate a...

Cohance Lifesciences Ltd. has gained 59.33% in the last 3 Months

Cohance Lifesciences Ltd.

07 Feb 2019

184.97

0.47%

SUVEN LIFE SCIENCES LTD

Buy: Cohance Lifesciences Ltd.

Geojit BNP Paribas

High emphasis on R&D; to provide long term stability while entry to formulations will bring margin benefits in future. CRAMS to provide steady revenue growth with 116+ active projects while a promising NCE (New Chemical Entity) pipeline of 13 molecules to drive the momentum....

Cohance Lifesciences Ltd. high volume past week with price gain of 34.44.

Cohance Lifesciences Ltd.

16 Nov 2018, 12:00AM

184.97

0.47%

Suven's (SVLS) weak Q2 numbers were driven by the absence of commercial CRAM supplies and...

Buy: Cohance Lifesciences Ltd.

Target

Emkay

supplies and a little, but insignificant, supply of Specialty CRAMS. 1HFY19 results broadly tracked expected growth trends overall, with CRAMS revenues up by c.9% to Rs2.5bn, Core CRAMS to Rs1.6bn (Rs910mn in Q1, Rs720mn in Q2), Commercial CRAMS...

Cohance Lifesciences Ltd. has gained 84.51% in the last 1 Year

Cohance Lifesciences Ltd.

10 Oct 2018

184.97

0.47%

Suven Life Sciences

Buy: Cohance Lifesciences Ltd.

ICICI Securities Limited

Cohance Lifesciences Ltd. has gained 51.24% in the last 1 Month

Cohance Lifesciences Ltd.

04 Sep 2018

184.97

0.47%

Suven Life Sci

Buy: Cohance Lifesciences Ltd.

Arihant Capital

Suven Life Sciences (SLS) is a compelling play on the recovery being witnessed in global R&D; spending, as reflected in strong fund raising by biotech start-ups as well as a fast-growing research pipeline across multiple stages of clinical trials. SLS has witnessed strong growth in revenue of 22.6% CAGR, whereas operating profit has shown growth of 42.4% CAGR over FY11 to FY18. With improved operating efficiency, we expect the EBITDA margin to expand at a higher rate than the gross margin due to lower than average R&D;...

Cohance Lifesciences Ltd. has gained 84.51% in the last 1 Year

Cohance Lifesciences Ltd.

08 Jun 2018

184.97

0.47%

Suven Life Sciences (SVLS) is a compelling play on the recovery being witnessed in global...

Buy: Cohance Lifesciences Ltd.

Emkay

Suven Life Sciences (SVLS) is a compelling play on the recovery being witnessed in global R&D; spending, as reflected in strong fund raising by biotech start-ups as well as a fastgrowing research pipeline across multiple stages of clinical trials. Also, the global Clinical Development & Manufacturing Organizations (CDMO) industry has undergone significant consolidation, both at the Clinical Research Organizations (CRO) level as well as at the API manufacturing level. As a result, fewer and only niche players are left in both clinical services and API manufacturing. SVLS enjoys a strong margin profile with EBITDA margin of 30%+. Earnings CAGR over FY18-20E is estimated at 19% and ROIC of 28%. We initiate coverage on SVLS with a...

Cohance Lifesciences Ltd. high volume past week with price gain of 34.44.

Is Suven Life Sciences Ltd. worth buying?

389 Votes:

Buy 80.46%

Sell 13.11%

Hold 6.43%